By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluorotechnics has reported that its preliminary fiscal-year 2011 revenues fell 67 percent from FY2010, as it continues to reorganize its business in a bid to stay afloat.

Separately, the Australian firm announced it has raised A$615,000 (US$646,807) for a planned acquisition in the "resources sector."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.